Cargando…
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed at evaluating the seroconversion elicited by COVID-19 vaccine over the entire vaccination cycle including the booster dose. Among 478 unselected ASD patients or...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271490/ https://www.ncbi.nlm.nih.gov/pubmed/35841684 http://dx.doi.org/10.1016/j.jaut.2022.102866 |
_version_ | 1784744692136542208 |
---|---|
author | Ferri, Clodoveo Gragnani, Laura Raimondo, Vincenzo Visentini, Marcella Giuggioli, Dilia Lorini, Serena Foti, Rosario Cacciapaglia, Fabio Caminiti, Maurizio Olivo, Domenico Cuomo, Giovanna Pellegrini, Roberta Pigatto, Erika Urraro, Teresa Naclerio, Caterina Tavoni, Antonio Puccetti, Lorenzo Cavazzana, Ilaria Ruscitti, Piero Vadacca, Marta La Gualana, Francesca Cozzi, Franco Spinella, Amelia Visalli, Elisa Bosco, Ylenia Dal Amato, Giorgio Masini, Francesco Mariano, Giuseppa Pagano Brittelli, Raffaele Aiello, Vincenzo Scorpiniti, Daniela Rechichi, Giovanni Varcasia, Giuseppe Monti, Monica Elia, Giusy Franceschini, Franco Casato, Milvia Ursini, Francesco Giacomelli, Roberto Fallahi, Poupak Santini, Stefano Angelo Iannone, Florenzo Salvarani, Carlo Zignego, Anna Linda Antonelli, Alessandro |
author_facet | Ferri, Clodoveo Gragnani, Laura Raimondo, Vincenzo Visentini, Marcella Giuggioli, Dilia Lorini, Serena Foti, Rosario Cacciapaglia, Fabio Caminiti, Maurizio Olivo, Domenico Cuomo, Giovanna Pellegrini, Roberta Pigatto, Erika Urraro, Teresa Naclerio, Caterina Tavoni, Antonio Puccetti, Lorenzo Cavazzana, Ilaria Ruscitti, Piero Vadacca, Marta La Gualana, Francesca Cozzi, Franco Spinella, Amelia Visalli, Elisa Bosco, Ylenia Dal Amato, Giorgio Masini, Francesco Mariano, Giuseppa Pagano Brittelli, Raffaele Aiello, Vincenzo Scorpiniti, Daniela Rechichi, Giovanni Varcasia, Giuseppe Monti, Monica Elia, Giusy Franceschini, Franco Casato, Milvia Ursini, Francesco Giacomelli, Roberto Fallahi, Poupak Santini, Stefano Angelo Iannone, Florenzo Salvarani, Carlo Zignego, Anna Linda Antonelli, Alessandro |
author_sort | Ferri, Clodoveo |
collection | PubMed |
description | Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed at evaluating the seroconversion elicited by COVID-19 vaccine over the entire vaccination cycle including the booster dose. Among 478 unselected ASD patients originally evaluated at the end of the first vaccination cycle (time 1), 344 individuals were re-evaluated after a 6-month period (time 2), and 244 after the booster vaccine dose (time 3). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was assessed by measuring serum IgG-neutralizing antibody (NAb) on samples obtained at the three time points in both patients and 502 age-matched controls. In the 244 ASD group that received booster vaccine and monitored over the entire follow-up, the mean serum NAb levels (time 1, 2, and 3: 696.8 ± 52.68, 370.8 ± 41.92, and 1527 ± 74.16SD BAU/mL, respectively; p < 0.0001) were constantly lower compared to controls (p < 0.0001), but they significantly increased after the booster dose compared to the first two measurements (p < 0.0001). The percentage of patients with absent/suboptimal response to vaccine significantly decreased after the booster dose compared to the first and second evaluations (time 1, 2, and 3: from 28.2% to 46.3%, and to 7.8%, respectively; p < 0.0001). Of note, the percentage of patients with absent/suboptimal response after the booster dose was significantly higher compared to controls (19/244, 7.8% vs 1/502, 0.2%; p < 0.0001). Similarly, treatment with immune-modifiers increased the percentage of patients exhibiting absent/suboptimal response (16/122, 13.1% vs 3/122, 2.46%; p = 0.0031). Overall, the above findings indicate the usefulness of booster vaccine administration in ASD patients. Moreover, the persistence of a significantly higher percentage of individuals without effective seroconversion (7.8%), even after the booster dose, warrants for careful monitoring of NAb levels in all ASD patients to identify those with increased risk of infection. In this particularly frail patients’ setting, tailored vaccination and/or therapeutic strategy are highly advisable. |
format | Online Article Text |
id | pubmed-9271490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92714902022-07-11 Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases Ferri, Clodoveo Gragnani, Laura Raimondo, Vincenzo Visentini, Marcella Giuggioli, Dilia Lorini, Serena Foti, Rosario Cacciapaglia, Fabio Caminiti, Maurizio Olivo, Domenico Cuomo, Giovanna Pellegrini, Roberta Pigatto, Erika Urraro, Teresa Naclerio, Caterina Tavoni, Antonio Puccetti, Lorenzo Cavazzana, Ilaria Ruscitti, Piero Vadacca, Marta La Gualana, Francesca Cozzi, Franco Spinella, Amelia Visalli, Elisa Bosco, Ylenia Dal Amato, Giorgio Masini, Francesco Mariano, Giuseppa Pagano Brittelli, Raffaele Aiello, Vincenzo Scorpiniti, Daniela Rechichi, Giovanni Varcasia, Giuseppe Monti, Monica Elia, Giusy Franceschini, Franco Casato, Milvia Ursini, Francesco Giacomelli, Roberto Fallahi, Poupak Santini, Stefano Angelo Iannone, Florenzo Salvarani, Carlo Zignego, Anna Linda Antonelli, Alessandro J Autoimmun Article Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed at evaluating the seroconversion elicited by COVID-19 vaccine over the entire vaccination cycle including the booster dose. Among 478 unselected ASD patients originally evaluated at the end of the first vaccination cycle (time 1), 344 individuals were re-evaluated after a 6-month period (time 2), and 244 after the booster vaccine dose (time 3). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was assessed by measuring serum IgG-neutralizing antibody (NAb) on samples obtained at the three time points in both patients and 502 age-matched controls. In the 244 ASD group that received booster vaccine and monitored over the entire follow-up, the mean serum NAb levels (time 1, 2, and 3: 696.8 ± 52.68, 370.8 ± 41.92, and 1527 ± 74.16SD BAU/mL, respectively; p < 0.0001) were constantly lower compared to controls (p < 0.0001), but they significantly increased after the booster dose compared to the first two measurements (p < 0.0001). The percentage of patients with absent/suboptimal response to vaccine significantly decreased after the booster dose compared to the first and second evaluations (time 1, 2, and 3: from 28.2% to 46.3%, and to 7.8%, respectively; p < 0.0001). Of note, the percentage of patients with absent/suboptimal response after the booster dose was significantly higher compared to controls (19/244, 7.8% vs 1/502, 0.2%; p < 0.0001). Similarly, treatment with immune-modifiers increased the percentage of patients exhibiting absent/suboptimal response (16/122, 13.1% vs 3/122, 2.46%; p = 0.0031). Overall, the above findings indicate the usefulness of booster vaccine administration in ASD patients. Moreover, the persistence of a significantly higher percentage of individuals without effective seroconversion (7.8%), even after the booster dose, warrants for careful monitoring of NAb levels in all ASD patients to identify those with increased risk of infection. In this particularly frail patients’ setting, tailored vaccination and/or therapeutic strategy are highly advisable. Elsevier Ltd. 2022-07 2022-07-11 /pmc/articles/PMC9271490/ /pubmed/35841684 http://dx.doi.org/10.1016/j.jaut.2022.102866 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Ferri, Clodoveo Gragnani, Laura Raimondo, Vincenzo Visentini, Marcella Giuggioli, Dilia Lorini, Serena Foti, Rosario Cacciapaglia, Fabio Caminiti, Maurizio Olivo, Domenico Cuomo, Giovanna Pellegrini, Roberta Pigatto, Erika Urraro, Teresa Naclerio, Caterina Tavoni, Antonio Puccetti, Lorenzo Cavazzana, Ilaria Ruscitti, Piero Vadacca, Marta La Gualana, Francesca Cozzi, Franco Spinella, Amelia Visalli, Elisa Bosco, Ylenia Dal Amato, Giorgio Masini, Francesco Mariano, Giuseppa Pagano Brittelli, Raffaele Aiello, Vincenzo Scorpiniti, Daniela Rechichi, Giovanni Varcasia, Giuseppe Monti, Monica Elia, Giusy Franceschini, Franco Casato, Milvia Ursini, Francesco Giacomelli, Roberto Fallahi, Poupak Santini, Stefano Angelo Iannone, Florenzo Salvarani, Carlo Zignego, Anna Linda Antonelli, Alessandro Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases |
title | Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases |
title_full | Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases |
title_fullStr | Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases |
title_full_unstemmed | Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases |
title_short | Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases |
title_sort | absent or suboptimal response to booster dose of covid-19 vaccine in patients with autoimmune systemic diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271490/ https://www.ncbi.nlm.nih.gov/pubmed/35841684 http://dx.doi.org/10.1016/j.jaut.2022.102866 |
work_keys_str_mv | AT ferriclodoveo absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT gragnanilaura absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT raimondovincenzo absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT visentinimarcella absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT giuggiolidilia absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT loriniserena absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT fotirosario absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT cacciapagliafabio absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT caminitimaurizio absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT olivodomenico absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT cuomogiovanna absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT pellegriniroberta absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT pigattoerika absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT urraroteresa absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT nacleriocaterina absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT tavoniantonio absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT puccettilorenzo absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT cavazzanailaria absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT ruscittipiero absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT vadaccamarta absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT lagualanafrancesca absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT cozzifranco absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT spinellaamelia absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT visallielisa absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT boscoyleniadal absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT amatogiorgio absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT masinifrancesco absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT marianogiuseppapagano absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT brittelliraffaele absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT aiellovincenzo absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT scorpinitidaniela absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT rechichigiovanni absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT varcasiagiuseppe absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT montimonica absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT eliagiusy absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT franceschinifranco absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT casatomilvia absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT ursinifrancesco absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT giacomelliroberto absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT fallahipoupak absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT santinistefanoangelo absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT iannoneflorenzo absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT salvaranicarlo absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT zignegoannalinda absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases AT antonellialessandro absentorsuboptimalresponsetoboosterdoseofcovid19vaccineinpatientswithautoimmunesystemicdiseases |